TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34041702
Drug: Upadacitinib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 7.5 mg
Study: 36498228
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 6 weeks
Study: 36498228
Drug: 770 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 770 mg/day of Tribulus terrestris L. (TT) for 6 weeks
Study: 36241249
Drug: Adjunctive plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive plasma exchange therapy
Study: 36241249
Drug: Intensive immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive immunosuppressive therapy
Study: 35631229
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (100 mg oral daily for 1 month)
Study: 32760093
Drug: Peribulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar anesthesia with 4 6 ml of 1% ropivacaine
Study: 35843923
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg tablet (test product)
Study: 35843923
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg tablet (reference product)
Study: 33465818
Drug: Regular daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular daily intake of PPIs
Study: 32352714
Drug: Open-label rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label rifaximin 550 mg 3 times daily for 2 weeks
Study: 32352714
Drug: Double-blind rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-blind rifaximin 550 mg 3 times daily
Study: 33979219
Drug: Low-frequency contact
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency contact ultrasonic debridement therapy (LFCUD) alone
Study: 616576545
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + sitagliptin (100 mg once daily)
Study: 35565077
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement therapy assisted using Bioptron Hyperlight Therapy
Study: 35565077
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement therapy alone
Study: 32595055
Drug: IV Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Lidocaine (5 cc = 100 mg)
Study: 32595055
Drug: IV Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Morphine sulfate (5 cc = 5 mg)
Study: 36380383
Drug: Real Time
Normalized name: MENTHOL 15 mg in 1 g TOPICAL CREAM [Real Time Pain Relief Foot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real Time Medication Monitoring (RTMM)
Study: 36380383
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of self-report and pharmacy refill count
Study: 36380383
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three measures (self-report, pharmacy refill count, RTMM)
Study: 32567217
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (3 mg/mL)
Study: 32567217
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (1 mg/mL)
Study: 33337391
Drug: Dexamethasone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.75 mg/kg/day for 6 days)
Study: 39256427
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB)
Study: 34904270
Drug: Linzagolix 25–200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linzagolix 25–200 mg daily
Study: 33368499
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg/day
Study: 32064621
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus β‐D mannuronic acid (M2000)
Study: 39762953
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (control)
Study: 36244652
Drug: High-dose losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose losartan (150 mg/day)
Study: 32735145
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg etanercept
Study: 32735145
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg etanercept
Study: 33927121
Drug: (tissue inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: (tissue inhibitor of metalloproteinases‐2)•(insulin‐like growth factor‐binding protein 7) patterns
Study: 35276894
Drug: Higher Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Protein (HP) diet (1.2 g/kg BW)
Study: 35276894
Drug: Normal Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Protein (NP) diet (0.8 g/kg BW)
Study: 32624444
Drug: Carbohydrate antigen
Normalized name: Carbohydrate antigen 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate antigen 125-guided diuretic strategy
Study: 32674229
Drug: Carbohydrate‐whey protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐whey protein solution (CHP)
Study: 33586360
Drug: Anlotinib 12
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12 mg on days 1–14 (repeated every 21 days)
Study: 33875429
Drug: Tebipenem pivoxil
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 600 mg
Study: 33875429
Drug: Tebipenem pivoxil
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebipenem pivoxil hydrobromide (TBP‐PI‐HBr) 1200 mg
Study: 33409459
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day
Study: 34676521
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) combined with standardized post-resuscitation care bundle (PRCB)
Study: 32933452
Drug: Pain Neuroscience
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Neuroscience Education (PNE) sessions (six 15-minute sessions) along with physical therapy
Study: 32933452
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy with PNE
Study: 33541288
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care of treatment & SBRT to all bone metastases
Study: 34327227
Drug: Pulsed Electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Electromagnetic Field Treatment (PEMF)
Study: 33791385
Drug: Periocular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injection of triamcinolone acetonide (TA) administered once every 3 weeks for a total of 3 times.
Study: 33791385
Drug: Subpalpebral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subpalpebral injection of botulinum toxin type A (BTXA) given as a single administration.
Study: 33994585
Drug: C-Reactive Protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-Reactive Protein (CRP) and Sequential Organ Failure Assessment (SOFA) score at admission
Study: 36239414
Drug: Psychoanalytic Treatment
Normalized name: PSYCHOANALEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic Treatment (PAT)
Study: 34498484
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) for VTE prevention
Study: 35978355
Drug: Integrated smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated smoking cessation therapy consisting of weekly brief behavioural interventions and prescription-free nicotine replacement products (nicotine lozenges, patches, and chewing gum) for 16 weeks (with an option to extend by 8 weeks).
Study: 33518321
Drug: Glycyrrhiza polysaccharide
Normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhiza polysaccharide (GCP) 200 mg/kg
Study: 33518321
Drug: Glycyrrhiza polysaccharide
Normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhiza polysaccharide (GCP) 500 mg/kg
Study: 33518321
Drug: Glycyrrhiza polysaccharide
Normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhiza polysaccharide (GCP) 1,000 mg/kg
Study: 33518321
Drug: Glycyrrhiza polysaccharide
Normalized name: GLYCYRRHIZA
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhiza polysaccharide (GCP) 1,500 mg/kg
Study: 38319865
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg
Study: 33724473
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with simultaneous bone augmentation
Study: 36410472
Drug: efdamrofusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efdamrofusp alfa 2 mg
Study: 36410472
Drug: efdamrofusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efdamrofusp alfa 4 mg
Study: 34301613
Drug: aflibercept 2
Normalized name: ziv-aflibercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: aflibercept 2 mg
Study: 36410472
Drug: efdamrofusp alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: efdamrofusp alfa 2 mg and 4 mg
Study: 32498248
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day ubiquinol (Ubq150)
Study: 36472134
Drug: lemborexant 10
Normalized name: lemborexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant 10 mg
Study: 33576735
Drug: lemborexant 5
Normalized name: lemborexant 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant 5 mg and 10 mg
Study: 35046055
Drug: IP cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker), and IP IFNa at 2, 6, and 18 million units (MU) in cohorts 2, 3, and 4 respectively
Study: 35046055
Drug: IP cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP cisplatin, IP rintatolimod (dsRNA, TLR3 ligand), oral celecoxib (COX-2 blocker)
Study: 33020646
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of dabrafenib and trametinib
Study: 33020646
Drug: Continuous dosing
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous dosing of dabrafenib and trametinib
Study: 33513714
Drug: Marine protein
Normalized name: Ascorbic Acid/Biotin/Coenzyme Q10/Grape Seed Extract/Hydrated Silica/Marine Protein/Mucopolysaccharides/Selenium/Vitamin A/Vitamin D/Vitamin E/Zinc 62 MG-50 MCG-5 MG-15 MG-60 MG-83 MCG-2417 IU-51 IU-25.5 IU-1.8 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine protein hydrolysate (MPH) 3 g
Study: 32675537
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (2 postoperative doses)
Study: 32675537
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 postoperative doses)
Study: 32488856
Drug: Coriandrum sativum
Normalized name: CORIANDRUM SATIVUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coriandrum sativum extract (300 mg/kg/day)
Study: 32030921
Drug: 7-day proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day proton pump inhibitor (PPI)-based standard triple therapy (STT; PPI-clarithromycin-amoxicillin)
Study: 32030921
Drug: 14-day proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day proton pump inhibitor (PPI)-based standard triple therapy (STT; PPI-clarithromycin-amoxicillin)
Study: 35850884
Drug: Eyebrow suspension
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eyebrow suspension with nylon thread (ESN)
Study: 32417468
Drug: Other healthcare-related
Normalized name: OTHER DRUGS FOR ACID RELATED DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other healthcare-related resources (e.g., CDC, WebMD)
Study: 32074281
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal pessaries 400 mg bid
Study: 32074281
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal gel 90 mg od
Study: 32396179
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with open reduction and internal plate fixation (n=38)
Study: 36104702
Drug: Vaporized nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaporized nicotine products (VNPs) - pod (40 mg/mL nicotine salt) and tank device (18 mg/mL freebase nicotine)
Study: 36104702
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) - gum or lozenge (4 mg)
Study: 33224416
Drug: Ibuprofen (10mg/kg)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (10mg/kg)
Study: 33224416
Drug: Paracetamol (15mg/kg)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (15mg/kg)
Study: 36939774
Drug: Ibuprofen treatment
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen treatment
Study: 35988360
Drug: CIPRO+FLUO (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPRO+FLUO (ciprofloxacin 0.3 % and fluocinolone acetonide 0.025 % otic solution)
Study: 35988360
Drug: CIPRO (ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPRO (ciprofloxacin 0.3 % otic solution)
Study: 35988360
Drug: FLUO (fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLUO (fluocinolone acetonide 0.025 % otic solution)
Study: 34939004
Drug: Exercise is
Normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise is Medicine (EIM) intervention framework (mHealth components plus twice‐weekly small‐group directed exercise sessions)
Study: 37640035
Drug: Colchicine 0.5
Normalized name: colchicine 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.5 mg twice daily
Study: 33752164
Drug: sprifermin 100
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprifermin 100 µg every 6 months (q6mo)
Study: 34913147
Drug: Simple Combination
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Combination Therapy (SCT)
Study: 32514040
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of oxytocin (OT) in the minimal social contact (MSC) condition
Study: 32514040
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of oxytocin (OT) in the no-social-contact (NoC) condition
Study: 35019769
Drug: Biotène dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotène dry mouth oral rinse
Study: 32820573
Drug: Epidemiological agent-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidemiological agent-based models (ABMs) such as AceMod for the COVID-19 epidemic in Australia
Study: 32820573
Drug: Epidemiological agent-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidemiological agent-based models (ABMs)
Study: 37222252
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/d)
Study: 34265462
Drug: mRNA BNT162b2
Normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA BNT162b2 (2 doses)
Study: 34265462
Drug: mRNA-1273 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (1 dose)
Study: 34265462
Drug: mRNA-1273 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (2 doses)
Study: 33338947
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus metformin
Study: 35987487
Drug: Trauma-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Therapy (TFT) - Prolonged Exposure or Cognitive Processing Therapy
Study: 35987487
Drug: Non-Trauma-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Trauma-Focused Therapy (NTFT) - Present Centered Therapy (PCT)
Study: 34477993
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy
Study: 35320927
Drug: ADD (pecans
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADD (pecans 68 g/d)
Study: 35320927
Drug: SUB (pecans
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUB (pecans 68 g/d with isocaloric substitution)
Study: 33527654
Drug: Ambulatory medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory medication intervention (diuretic up-titration PRN)
Study: 34085466
Drug: Joint administration
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint administration of acupuncture, western and herbal medicines, and bamboo-jar-cupping (kept for 10 min), treatment conducted once a day for 2 weeks.
Study: 34085466
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (acupuncture + cupping) vs Control group (acupuncture + conventional western and herbal medicines).
Study: 616505834
Drug: Fibre-enriched nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-enriched nutrition solution
Study: 33054003
Drug: Improved methods
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved methods of physical training with interval cyclic training on treadmills and sensory tracks, therapeutic exercises in the gym (daily, 5 times a week, for a course of 10 procedures)
Study: 33054003
Drug: Enhanced external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced external counterpulsation, general dry air carbon dioxide, infrared matrix laser therapy
Study: 32447296
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg IV every 4 weeks for 24 cycles) + concurrent chemoradiotherapy
Study: 32447296
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + concurrent chemoradiotherapy
Study: 35177777
Drug: Oral hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydroxyurea 10-20 mg/kg/day
Study: 32108254
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group (no implant material injection)
Study: 36201851
Drug: ShipShape enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: ShipShape enhanced with acceptance and commitment therapy
Study: 35841586
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of danofloxacin at 10 mg/kg
Study: 35841586
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of danofloxacin at 10 mg/kg
Study: 35841586
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of danofloxacin at 10 mg/kg
Study: 32752228
Drug: Brief group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief group cognitive behavioral therapy (BG-CBT) - six brief weekly sessions
Study: 33220462
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 125 μg
Study: 33220462
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 250 μg
Study: 33220462
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 1125 μg
Study: 35501736
Drug: 6-thioguanine (6TG)
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-thioguanine (6TG) at a low dose of 2.5–12.5 mg/m2/day, combined with reduced 6-mercaptopurine (6MP) starting dose of 50 mg/m2/day
Study: 35501736
Drug: Methotrexate (MTX)/6-mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX)/6-mercaptopurine (6MP) maintenance therapy
Study: 32776907
Drug: Kuntai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuntai capsule
Study: 32067512
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg deferasirox
Study: 32067512
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole and 30 mg/kg deferasirox
Study: 32067512
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vitamin E and 30 mg/kg deferasirox
Study: 32067512
Drug: 420 mg
Normalized name: choline 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420 mg silymarin and 30 mg/kg deferasirox
Study: 35821886
Drug: Diagnostic performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic performance of ADC value to differentiate CC and normal cervix
Study: 32901379
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using diode laser (980 nm, 0.3 W) for 10 seconds at six spots along the midpalatal suture during active and passive phases of rapid palatal expansion.